BACKGROUND: The recent discovery of a mecA homologue (mecA(LGA251)) with a high level of variability between the two gene variants suggested that Staphylococcus aureus harbouring mecA(LGA251) could be wrongly identified as methicillin-susceptible S. aureus (MSSA), in the absence of antimicrobial susceptibility testing. METHODS: In this context we designed a real-time quadruplex PCR assay to distinguish unequivocally between mecA and mecA(LGA251), alongside the nuc gene (a species-specific marker) and detection of the lukS-PV gene [encoding the Panton-Valentine leucocidin (PVL) toxin]. RESULTS AND DISCUSSION: The assay was validated using a collection of (i) PVL-positive and PVL-negative MSSA and methicillin-resistant S. aureus (MRSA) and (ii) known MRSA harbouring mecA(LGA251) from the UK, Denmark and France. When applied to a retrospective collection of oxacillin-non-susceptible, mecA-negative human isolates, three were found to encode mecA(LGA251), including one from blood, representing the first hitherto recognized case of bacteraemia due to S. aureus possessing the mecA(LGA251) in England. Finally, the assay was introduced into the routine Staphylococcus Reference Unit (HPA Microbiology Services, London, UK) workflow in August 2011, and, during the first 5 months of use, 10 isolates harbouring the mecA homologue were identified out of 2263 S. aureus tested, suggesting a low but continuous circulation within the human population in England.
BACKGROUND: The recent discovery of a mecA homologue (mecA(LGA251)) with a high level of variability between the two gene variants suggested that Staphylococcus aureus harbouring mecA(LGA251) could be wrongly identified as methicillin-susceptible S. aureus (MSSA), in the absence of antimicrobial susceptibility testing. METHODS: In this context we designed a real-time quadruplex PCR assay to distinguish unequivocally between mecA and mecA(LGA251), alongside the nuc gene (a species-specific marker) and detection of the lukS-PV gene [encoding the Panton-Valentine leucocidin (PVL) toxin]. RESULTS AND DISCUSSION: The assay was validated using a collection of (i) PVL-positive and PVL-negative MSSA and methicillin-resistant S. aureus (MRSA) and (ii) known MRSA harbouring mecA(LGA251) from the UK, Denmark and France. When applied to a retrospective collection of oxacillin-non-susceptible, mecA-negative human isolates, three were found to encode mecA(LGA251), including one from blood, representing the first hitherto recognized case of bacteraemia due to S. aureus possessing the mecA(LGA251) in England. Finally, the assay was introduced into the routine Staphylococcus Reference Unit (HPA Microbiology Services, London, UK) workflow in August 2011, and, during the first 5 months of use, 10 isolates harbouring the mecA homologue were identified out of 2263 S. aureus tested, suggesting a low but continuous circulation within the human population in England.
Authors: H S Tunsjø; S Kalyanasundaram; M M Worren; T M Leegaard; A E F Moen Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-09 Impact factor: 3.267
Authors: Saara Sillanpää; Sami Oikarinen; Markku Sipilä; Lenka Kramna; Markus Rautiainen; Heini Huhtala; Janne Aittoniemi; Jussi Laranne; Heikki Hyöty; Ondrej Cinek Journal: J Clin Microbiol Date: 2016-07-13 Impact factor: 5.948
Authors: Eric Y Kok; Jesus G Vallejo; Lauren M Sommer; Louie Rosas; Sheldon L Kaplan; Kristina G Hulten; J Chase McNeil Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: K Saeed; N Ahmad; M Dryden; N Cortes; P Marsh; A Sitjar; S Wyllie; S Bourne; J Hemming; C Jeppesen; S Green Journal: Infection Date: 2014-06-12 Impact factor: 3.553